This study is looking at how Gabapentin, an FDA-approved medication, affects people who have both Bipolar Disorder and Cannabis Use Disorder. You would be assigned to take either Gabapentin or a placebo (an inactive pill) for 17 days. Researchers will use Magnetic Resonance Imaging (MRI) scans to measure changes in brain chemicals, specifically GABA, which is thought to be involved in these conditions. The study is looking for 68 participants, aged 18 to 65, who have been diagnosed with Bipolar I or II Disorder or Schizoaffective Disorder, Bipolar Type, and moderate to severe cannabis use disorder. The study's main goal is to see if Gabapentin can help restore balance in brain chemicals.

Study design

This is an interventional study, meaning participants receive a specific treatment. You would be randomly assigned to receive either Gabapentin or a placebo, and the study plans to enroll 68 participants.

What's involved

You would have 5 study visits over 17 days, including two MRI brain scans. You would also complete questionnaires and clinical interviews.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures changes from baseline to the end of treatment, which is approximately 17 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.